替吉奥与卡培他滨同步放疗治疗复发性结直肠癌疗效与安全性的Meta分析  

Meta-analysis of the Efficacy and Safety of Simultaneous Therapy of Tegafur and Capecitabine for Recurrent Colorectal Cancer

作　　者：郭雪 石学军[1] GUO Xue;SHI Xue-jun(Department of Oncology,Yongchuan Hospital,Chongqing Medical University,Chongqing 402160,China)

机构地区：[1]重庆医科大学附属永川医院肿瘤科,重庆402160

出　　处：《医学信息》2020年第7期71-75,共5页Journal of Medical Information

摘　　要：目的对替吉奥与卡培他滨同步放疗在复发性结直肠癌的疗效及安全性进行Meta分析。方法2017年9月~2019年12月计算机检索PubMed、The Cochrane Library、Embase、VIP、CKNI、万方数据库,按照纳入和排除标准筛选文献和提取资料后,采用RevMan 5.3软件进行Meta分析。结果最终纳入8篇文献,包括706例患者。Meta分析结果显示,替吉奥同步放疗较卡培他滨能有效改善复发性结直肠癌的客观缓解率,差异有统计学意义[OR=2.23,95%CI(1.59,3.13)],P<0.00001];替吉奥同步放疗较卡培他滨能有效改善复发性结直肠癌的疾病控制率,差异有统计学意义[OR=3.63,95%CI(2.00,6.57),P<0.0001];第1、第2、第3年生存率比较,差异有统计学意义[OR=3.48,95%CI(1.98,6.13),P<0.0001]、[OR=2.35,95%CI(1.55,3.55),P<0.0001]、[OR=1.94,95%CI(1.30,2.90),P=0.001]。替吉奥同步放疗手足综合征发生率低于卡培他滨同步放疗,差异有统计学意义[OR=0.33,95%CI(0.13,0.81),P=0.02];恶心、呕吐等消化道反应[OR=0.74,95%CI(0.5,1.10),P=0.14]、放射性直肠炎[OR=0.72,95%CI(0.42,1.24),P=0.24]与对照组比较,差异无统计学意义。结论在治疗复发性结直肠癌方面,替吉奥同步放疗与卡培他滨同步放疗比较,前者能有效改善客观缓解率,在手足综合征方面具有更良好的安全性。Objective To conduct a meta-analysis on the efficacy and safety of simultaneous radiotherapy of Tegafur and capecitabine in recurrent colorectal cancer.Methods The computer searched PubMed,The Cochrane Library,Embase,VIP,CKNI,Wanfang databases,after screening literature and extracting data according to the inclusion and exclusion criteria,using RevMan 5.3 software for Meta analysis from September 2017 to December 2019.Results 8 articles were finally included,including 706 patients.Meta analysis results showed that Tegafur simultaneous radiotherapy can effectively improve the objective remission rate of recurrent colorectal cancer compared with capecitabine,the difference was statistically significant[OR=2.23,95%CI(1.59,3.13)],P<0.00001];Tegafur simultaneous radiotherapy can effectively improve the disease control rate of recurrent colorectal cancer compared with capecitabine,the difference was statistically significant[OR=3.63,95%CI(2.00,6.57),P<0.0001];Comparison of survival rates in the first,second,and third years respectively,the difference was statistically significant[OR=3.48,95%CI(1.98,6.13),P<0.0001],[OR=2.35,95%CI(1.55,3.55),P<0.0001],[OR=1.94,95%CI(1.30,2.90),P=0.001].The incidence of hand-foot syndrome was lower than capecitabine in simultaneous radiotherapy for Tegafur,the difference was statistically significant[OR=0.33,95%CI(0.13,0.81),P=0.02];nausea,vomiting and other gastrointestinal reactions[OR=0.74,95%CI(0.5,1.10),P=0.14],radiation proctitis[OR=0.72,95%CI(0.42,1.24),P=0.24]compared with the control group,the difference was not statistically significant.Conclusion In the treatment of recurrent colorectal cancer,compared with synchronous radiotherapy of Tegafur and capecitabine,the former can effectively improve the objective remission rate and has better safety in hand-foot syndrome.

关 键 词：替吉奥 卡培他滨 放疗 结直肠癌 META分析 

分 类 号：R735.2[医药卫生—肿瘤]